PSME3

Proteasome activator complex subunit 3 · P61289 · PSME3 on Sugi Atlas →

0 patent compounds predicted against PSME3, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PSME3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas PHASE2COMPLETED
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma PHASE2WITHDRAWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Biologic Correlative Taxotere/AC PHASE2COMPLETED
3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS) PHASE2COMPLETED
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) PHASE2ACTIVE_NOT_RECRUITING
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
A Natural History Study of Angelman Syndrome nanRECRUITING
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI nanRECRUITING
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults nanNOT_YET_RECRUITING
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PSME3 binder may also engage these)

ProteinNameSimilarity
Q5RFD3 1.000 Q5RFD3 →
Q4R4V3 1.000 Q4R4V3 →
P61291 1.000 P61291 →
P61290 1.000 P61290 →
Q5F3J5 1.000 Q5F3J5 →
Q5ZHV2 0.977 Q5ZHV2 →
Q7T322 0.976 Q7T322 →
Q5PPY2 0.976 Q5PPY2 →
F4HPA7 0.976 F4HPA7 →
O94915 0.976 O94915 →
Q6PC45 0.975 Q6PC45 →
A8E5U3 0.975 A8E5U3 →
Q9CQI9 0.975 Q9CQI9 →
Q86UW7 0.975 Q86UW7 →
O57595 0.975 O57595 →
A5WUL3 0.975 A5WUL3 →
Q5XPI4 0.974 Q5XPI4 →
Q6DKG0 0.974 Q6DKG0 →
Q8R3N6 0.974 Q8R3N6 →
Q8BYR5 0.974 Q8BYR5 →
Q95JW3 0.973 Q95JW3 →
Q96HR3 0.973 Q96HR3 →
Q96FV9 0.973 Q96FV9 →
Q9DBA9 0.973 Q9DBA9 →
Q5RAX7 0.973 Q5RAX7 →
Q6PE87 0.973 Q6PE87 →
Q6GQ95 0.973 Q6GQ95 →
Q8NAN2 0.972 Q8NAN2 →
Q6GLR7 0.972 Q6GLR7 →
Q6P4S8 0.972 Q6P4S8 →